Can GSK’s new R&D strategy resuscitate the worst performer in Big Pharma?
The view from John Carroll
The new pharma chief at GSK is laying out their new pipeline game plan, which should begin in earnest once Hal Barron arrives to take over R&D.
In an interview with Reuters, Luke Miels outlined plans to rev up a dormant business development operation $GSK, jumping off the sidelines to start licensing in early-stage drugs in cancer and immunology.
The initial pipeline focus at GSK will center on its BCMA-targeting multiple myeloma program, NY-ESO — partnered with Adaptimmune — and ICOS. This will play out as the company launches its new shingles vaccine, an HIV drug widely tapped as a blockbuster and its latest three-in-one inhaler Trelegy.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.